Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Non Small Cell Lung Cancer NSCLC × ceralasertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Breast Neoplasms 2 Bile Duct Neoplasms 2 Uterine Cervical Neoplasms 1 Thoracic Neoplasms 1 Small Cell Lung Carcinoma 1 SCLC 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Prostatic Neoplasms 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1 Osteosarcoma 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasms by Site 1 Lung Diseases 1 High Grade Serous Carcinoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Fallopian Tube Neoplasms 1 Extensive Stage Small Cell Lung Cancer 1 Endometrial Neoplasms 1 Cholangiocarcinoma 1 Carcinosarcoma 1 Carcinoma, Squamous Cell 1 Carcinoma, Endometrioid 1 Carcinoma, Bronchogenic 1

Interventions

durvalumab 1 ceralasertib 1 Radiotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06680050 2025-12-18

AUSTRAL

Mario Negri Institute for Pharmacological Research

Phase 2 Recruiting

Non Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡